Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombin generation

Thromb Haemost 2016; 115(04): 869-870
DOI: 10.1160/TH15-09-0699

Letter to the Editor

Schattauer GmbH

Romy M. W. Kremers

¹Synapse bv, Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands

,

Rob J. Wagenvoord

¹Synapse bv, Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands

,

H. Coenraad Hemker

¹Synapse bv, Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands

References
1 Jourdi G, Siguret V, Martin AC. et al. Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban. Thromb Haemost 2015; 114: 78-86.
2 Hemker HC, Kerdelo S, Kremers RM. Is there value in kinetic modeling of thrombin generation?. No (unless...). J Thromb Haemost 2012; 10: 1470-1477.
3 Mann KG. Is there value in kinetic modeling of thrombin generation? Yes. J Thromb Haemost 2012; 10: 1463-1469.
4 Butenas S, Mann KG. Caution in the interpretation of continuous thrombin generation assays. J Thromb Haemost 2007; 05: 1084-1085 author reply 1085-1087.
5 Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombinpotential. ThrombHaemost 1995; 74: 134-138.
6 Freyburger G, Macouillard G, Labrouche S. et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. ThrombRes 2011; 127: 457-465.
7 Douxfils J, Mullier F, Loosen C. et al. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012; 130: 956-966.
8 Jones KC, Mann KG. A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem 1994; 269: 23367-23373.